 Liping Yu
Concepts (245)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Autoantibodies | 54 | 2023 | 1496 | 5.620 |
Why?
| | Diabetes Mellitus, Type 1 | 58 | 2023 | 3710 | 3.790 |
Why?
| | Luminescent Measurements | 7 | 2021 | 75 | 3.000 |
Why?
| | Celiac Disease | 8 | 2023 | 294 | 2.330 |
Why?
| | Islets of Langerhans | 22 | 2023 | 803 | 2.070 |
Why?
| | Glutamate Decarboxylase | 15 | 2022 | 170 | 1.940 |
Why?
| | Electrochemical Techniques | 4 | 2021 | 52 | 1.760 |
Why?
| | High-Throughput Screening Assays | 3 | 2020 | 159 | 1.610 |
Why?
| | Zinc Transporter 8 | 10 | 2021 | 87 | 1.390 |
Why?
| | Autoimmune Diseases | 5 | 2020 | 460 | 1.370 |
Why?
| | Transglutaminases | 6 | 2023 | 156 | 1.280 |
Why?
| | Mass Screening | 11 | 2021 | 1267 | 1.260 |
Why?
| | Insulin Antibodies | 10 | 2016 | 105 | 1.210 |
Why?
| | Prediabetic State | 6 | 2015 | 253 | 1.140 |
Why?
| | Cation Transport Proteins | 8 | 2013 | 134 | 1.100 |
Why?
| | Receptor-Like Protein Tyrosine Phosphatases, Class 8 | 6 | 2016 | 63 | 0.980 |
Why?
| | Insulin | 20 | 2021 | 2406 | 0.930 |
Why?
| | Proinsulin | 4 | 2016 | 52 | 0.910 |
Why?
| | Sensitivity and Specificity | 14 | 2022 | 1936 | 0.900 |
Why?
| | Diagnostic Techniques, Endocrine | 3 | 2019 | 14 | 0.690 |
Why?
| | Autoantigens | 7 | 2021 | 428 | 0.660 |
Why?
| | Antibodies, Viral | 2 | 2023 | 624 | 0.560 |
Why?
| | Autoimmunity | 12 | 2023 | 908 | 0.540 |
Why?
| | Child, Preschool | 25 | 2023 | 10997 | 0.480 |
Why?
| | Child | 32 | 2023 | 21819 | 0.450 |
Why?
| | Biomarkers | 7 | 2022 | 4145 | 0.440 |
Why?
| | Glucose Intolerance | 1 | 2015 | 146 | 0.420 |
Why?
| | Infant | 19 | 2023 | 9395 | 0.410 |
Why?
| | Adolescent | 28 | 2023 | 21385 | 0.400 |
Why?
| | Humans | 62 | 2023 | 136803 | 0.390 |
Why?
| | Luminescence | 4 | 2016 | 38 | 0.380 |
Why?
| | Antibodies, Monoclonal, Murine-Derived | 1 | 2011 | 86 | 0.360 |
Why?
| | Peptide Fragments | 8 | 2016 | 705 | 0.320 |
Why?
| | Male | 29 | 2021 | 67330 | 0.310 |
Why?
| | Immunologic Factors | 1 | 2011 | 236 | 0.310 |
Why?
| | Diabetes Mellitus, Type 2 | 3 | 2022 | 2518 | 0.300 |
Why?
| | Protein Precursors | 3 | 2021 | 132 | 0.300 |
Why?
| | Female | 33 | 2021 | 72816 | 0.300 |
Why?
| | Quality Improvement | 1 | 2017 | 1163 | 0.300 |
Why?
| | Young Adult | 13 | 2021 | 13129 | 0.300 |
Why?
| | Radioimmunoassay | 4 | 2016 | 173 | 0.300 |
Why?
| | Radioligand Assay | 2 | 2009 | 48 | 0.290 |
Why?
| | Antibodies, Antinuclear | 1 | 2007 | 71 | 0.270 |
Why?
| | Reagent Kits, Diagnostic | 1 | 2007 | 42 | 0.270 |
Why?
| | Adult | 17 | 2023 | 37643 | 0.270 |
Why?
| | Disease Progression | 9 | 2019 | 2751 | 0.250 |
Why?
| | Risk Factors | 10 | 2021 | 10332 | 0.250 |
Why?
| | Seroepidemiologic Studies | 3 | 2023 | 165 | 0.240 |
Why?
| | Insulin-Secreting Cells | 3 | 2019 | 372 | 0.240 |
Why?
| | Addison Disease | 3 | 2012 | 43 | 0.230 |
Why?
| | Lupus Erythematosus, Systemic | 1 | 2007 | 242 | 0.220 |
Why?
| | CD4-Positive T-Lymphocytes | 4 | 2021 | 1095 | 0.210 |
Why?
| | Middle Aged | 11 | 2021 | 33239 | 0.210 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 5 | 2011 | 851 | 0.210 |
Why?
| | Case-Control Studies | 3 | 2021 | 3540 | 0.200 |
Why?
| | Isoenzymes | 2 | 2004 | 304 | 0.190 |
Why?
| | Disease Susceptibility | 2 | 2020 | 345 | 0.180 |
Why?
| | Electrochemistry | 1 | 2021 | 78 | 0.180 |
Why?
| | Interleukin 1 Receptor Antagonist Protein | 1 | 2022 | 253 | 0.180 |
Why?
| | China | 1 | 2021 | 216 | 0.180 |
Why?
| | Predictive Value of Tests | 6 | 2015 | 2022 | 0.180 |
Why?
| | Genotype | 9 | 2016 | 1914 | 0.170 |
Why?
| | Polymorphism, Genetic | 4 | 2017 | 659 | 0.170 |
Why?
| | GTP-Binding Proteins | 1 | 2021 | 161 | 0.170 |
Why?
| | DNA | 1 | 2007 | 1458 | 0.160 |
Why?
| | Spike Glycoprotein, Coronavirus | 1 | 2021 | 108 | 0.160 |
Why?
| | Follow-Up Studies | 6 | 2021 | 5106 | 0.160 |
Why?
| | Steroid 21-Hydroxylase | 3 | 2012 | 30 | 0.160 |
Why?
| | Health Fairs | 1 | 2019 | 9 | 0.160 |
Why?
| | Risk Assessment | 3 | 2020 | 3434 | 0.150 |
Why?
| | Colorado | 4 | 2023 | 4515 | 0.150 |
Why?
| | Prognosis | 5 | 2021 | 4013 | 0.150 |
Why?
| | Phosphoproteins | 1 | 2021 | 337 | 0.150 |
Why?
| | Prevalence | 3 | 2023 | 2710 | 0.150 |
Why?
| | Epitopes | 4 | 2021 | 480 | 0.140 |
Why?
| | Polyendocrinopathies, Autoimmune | 1 | 2017 | 18 | 0.140 |
Why?
| | Antibody Specificity | 4 | 2011 | 189 | 0.140 |
Why?
| | Cohort Studies | 3 | 2021 | 5704 | 0.140 |
Why?
| | Receptors, Antigen, T-Cell | 2 | 2023 | 718 | 0.140 |
Why?
| | Population Surveillance | 1 | 2020 | 474 | 0.140 |
Why?
| | Health Care Costs | 1 | 2020 | 385 | 0.130 |
Why?
| | Mice, Inbred NOD | 8 | 2008 | 600 | 0.130 |
Why?
| | Disease Management | 1 | 2020 | 624 | 0.130 |
Why?
| | HLA-DQ Antigens | 5 | 2016 | 181 | 0.120 |
Why?
| | T-Lymphocytes | 5 | 2023 | 1993 | 0.120 |
Why?
| | Risk | 2 | 2019 | 908 | 0.120 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2020 | 614 | 0.120 |
Why?
| | Incidence | 1 | 2021 | 2797 | 0.110 |
Why?
| | Aged | 5 | 2021 | 23808 | 0.110 |
Why?
| | Transcription Factors | 2 | 2017 | 1718 | 0.110 |
Why?
| | Protein Tyrosine Phosphatases | 3 | 2004 | 172 | 0.100 |
Why?
| | Poly I-C | 2 | 2004 | 63 | 0.100 |
Why?
| | Biopsy | 1 | 2016 | 1124 | 0.100 |
Why?
| | Reproducibility of Results | 2 | 2019 | 3265 | 0.100 |
Why?
| | Prospective Studies | 6 | 2023 | 7573 | 0.100 |
Why?
| | Histocompatibility Antigens Class I | 3 | 2009 | 202 | 0.090 |
Why?
| | HLA-DR Antigens | 4 | 2016 | 228 | 0.090 |
Why?
| | Iodine Radioisotopes | 1 | 2011 | 145 | 0.090 |
Why?
| | Pedigree | 3 | 2017 | 514 | 0.090 |
Why?
| | Glucose Tolerance Test | 1 | 2012 | 364 | 0.090 |
Why?
| | Rituximab | 1 | 2011 | 176 | 0.080 |
Why?
| | HLA-DR4 Antigen | 3 | 2011 | 78 | 0.080 |
Why?
| | HLA-DR3 Antigen | 3 | 2011 | 80 | 0.080 |
Why?
| | Drug Administration Schedule | 1 | 2011 | 785 | 0.080 |
Why?
| | Laboratories | 1 | 2009 | 112 | 0.070 |
Why?
| | Mice | 14 | 2008 | 17759 | 0.070 |
Why?
| | Longitudinal Studies | 3 | 2021 | 2829 | 0.070 |
Why?
| | Age of Onset | 3 | 2019 | 518 | 0.070 |
Why?
| | Family | 1 | 2012 | 665 | 0.070 |
Why?
| | Radioimmunoprecipitation Assay | 1 | 2007 | 6 | 0.070 |
Why?
| | Interferon-alpha | 2 | 2009 | 198 | 0.070 |
Why?
| | Diagnosis, Differential | 1 | 2011 | 1481 | 0.070 |
Why?
| | Antibody Formation | 1 | 2008 | 298 | 0.070 |
Why?
| | Histocompatibility Antigens | 1 | 2008 | 105 | 0.070 |
Why?
| | Recombinant Fusion Proteins | 1 | 2009 | 664 | 0.070 |
Why?
| | Peptides | 2 | 2023 | 981 | 0.070 |
Why?
| | Double-Blind Method | 1 | 2011 | 1982 | 0.060 |
Why?
| | Membrane Proteins | 2 | 2004 | 1163 | 0.060 |
Why?
| | CD4 Antigens | 2 | 2003 | 142 | 0.060 |
Why?
| | Animals | 15 | 2008 | 36850 | 0.060 |
Why?
| | C-Peptide | 2 | 2016 | 163 | 0.060 |
Why?
| | Anaphylaxis | 2 | 2004 | 105 | 0.060 |
Why?
| | Antibodies, Heterophile | 1 | 2004 | 14 | 0.060 |
Why?
| | Models, Biological | 1 | 2011 | 1773 | 0.050 |
Why?
| | Twins, Dizygotic | 1 | 2004 | 175 | 0.050 |
Why?
| | Endocrine System Diseases | 1 | 2004 | 35 | 0.050 |
Why?
| | Immunity, Mucosal | 1 | 2004 | 97 | 0.050 |
Why?
| | Mice, Inbred BALB C | 5 | 2004 | 1269 | 0.050 |
Why?
| | Siblings | 1 | 2004 | 227 | 0.050 |
Why?
| | Glycolipids | 1 | 2004 | 42 | 0.050 |
Why?
| | Remission Induction | 1 | 2004 | 288 | 0.050 |
Why?
| | Immunoglobulin E | 2 | 2021 | 342 | 0.050 |
Why?
| | Genetic Testing | 1 | 2005 | 453 | 0.050 |
Why?
| | Osteopontin | 1 | 2022 | 33 | 0.050 |
Why?
| | Fetal Blood | 1 | 2004 | 327 | 0.050 |
Why?
| | Epitopes, B-Lymphocyte | 1 | 2021 | 17 | 0.050 |
Why?
| | Diagnostic Techniques, Radioisotope | 1 | 2021 | 9 | 0.040 |
Why?
| | Seroconversion | 1 | 2021 | 46 | 0.040 |
Why?
| | Immunoglobulin D | 1 | 2021 | 30 | 0.040 |
Why?
| | Serologic Tests | 1 | 2021 | 54 | 0.040 |
Why?
| | Multicenter Studies as Topic | 1 | 2002 | 308 | 0.040 |
Why?
| | Canada | 1 | 2002 | 421 | 0.040 |
Why?
| | Diabetes Mellitus, Experimental | 1 | 2002 | 195 | 0.040 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2008 | 2184 | 0.040 |
Why?
| | Asymptomatic Diseases | 1 | 2021 | 89 | 0.040 |
Why?
| | Immunoglobulin G | 2 | 2021 | 887 | 0.040 |
Why?
| | Quality-Adjusted Life Years | 1 | 2020 | 113 | 0.040 |
Why?
| | Infant, Newborn | 4 | 2005 | 6032 | 0.040 |
Why?
| | Blood Specimen Collection | 1 | 2019 | 40 | 0.040 |
Why?
| | Immunoglobulin A | 1 | 2021 | 210 | 0.040 |
Why?
| | Costs and Cost Analysis | 1 | 2020 | 206 | 0.040 |
Why?
| | Immunoglobulin M | 1 | 2021 | 289 | 0.040 |
Why?
| | Age Factors | 2 | 2004 | 3286 | 0.040 |
Why?
| | Early Diagnosis | 1 | 2020 | 241 | 0.040 |
Why?
| | Methylation | 1 | 2019 | 230 | 0.040 |
Why?
| | Adrenocorticotropic Hormone | 2 | 2012 | 142 | 0.040 |
Why?
| | Proportional Hazards Models | 2 | 2016 | 1262 | 0.040 |
Why?
| | Tissue Donors | 1 | 2021 | 417 | 0.040 |
Why?
| | Cell Death | 1 | 2019 | 372 | 0.030 |
Why?
| | Alleles | 3 | 2009 | 890 | 0.030 |
Why?
| | Loss of Function Mutation | 1 | 2017 | 46 | 0.030 |
Why?
| | Community Health Services | 1 | 2019 | 227 | 0.030 |
Why?
| | Diabetic Ketoacidosis | 1 | 2020 | 200 | 0.030 |
Why?
| | Cost-Benefit Analysis | 1 | 2020 | 587 | 0.030 |
Why?
| | Clinical Trials as Topic | 1 | 2002 | 1044 | 0.030 |
Why?
| | Mice, Transgenic | 3 | 2008 | 2163 | 0.030 |
Why?
| | Cross-Sectional Studies | 2 | 2023 | 5424 | 0.030 |
Why?
| | Antibodies, Monoclonal | 1 | 2003 | 1430 | 0.030 |
Why?
| | Hydrocortisone | 2 | 2012 | 322 | 0.030 |
Why?
| | Phenotype | 2 | 2021 | 3189 | 0.030 |
Why?
| | HLA-DQ beta-Chains | 2 | 2009 | 63 | 0.030 |
Why?
| | Time Factors | 3 | 2016 | 6809 | 0.030 |
Why?
| | Antibody Affinity | 1 | 2016 | 60 | 0.030 |
Why?
| | Oligonucleotide Array Sequence Analysis | 2 | 2008 | 766 | 0.030 |
Why?
| | Protein Domains | 1 | 2017 | 289 | 0.030 |
Why?
| | Polymerase Chain Reaction | 2 | 2009 | 1059 | 0.030 |
Why?
| | Organ Specificity | 2 | 2007 | 304 | 0.030 |
Why?
| | Genome-Wide Association Study | 1 | 2022 | 1428 | 0.030 |
Why?
| | Proteomics | 1 | 2022 | 1109 | 0.030 |
Why?
| | Blood Glucose | 3 | 2016 | 2181 | 0.030 |
Why?
| | HEK293 Cells | 1 | 2017 | 729 | 0.030 |
Why?
| | Injections, Subcutaneous | 2 | 2004 | 154 | 0.030 |
Why?
| | Adoptive Transfer | 2 | 2005 | 224 | 0.030 |
Why?
| | Mice, SCID | 2 | 2005 | 366 | 0.030 |
Why?
| | Protein Tyrosine Phosphatase, Non-Receptor Type 1 | 2 | 2004 | 47 | 0.030 |
Why?
| | Multivariate Analysis | 1 | 2016 | 1507 | 0.020 |
Why?
| | Renin | 1 | 2012 | 35 | 0.020 |
Why?
| | Spleen | 2 | 2005 | 514 | 0.020 |
Why?
| | Administration, Oral | 2 | 2004 | 813 | 0.020 |
Why?
| | Feasibility Studies | 1 | 2015 | 951 | 0.020 |
Why?
| | Enzyme-Linked Immunospot Assay | 1 | 2011 | 36 | 0.020 |
Why?
| | Hypoglycemic Agents | 1 | 2020 | 1283 | 0.020 |
Why?
| | Immunization | 2 | 2004 | 411 | 0.020 |
Why?
| | Graves Disease | 1 | 2009 | 34 | 0.020 |
Why?
| | Homozygote | 1 | 2009 | 203 | 0.020 |
Why?
| | HLA-DRB1 Chains | 1 | 2009 | 112 | 0.020 |
Why?
| | Microsatellite Repeats | 1 | 2009 | 168 | 0.020 |
Why?
| | International Cooperation | 1 | 2009 | 198 | 0.020 |
Why?
| | Interferon-gamma | 1 | 2011 | 789 | 0.020 |
Why?
| | Mice, Knockout | 2 | 2005 | 3009 | 0.020 |
Why?
| | Pediatrics | 1 | 2015 | 1094 | 0.020 |
Why?
| | ROC Curve | 1 | 2009 | 545 | 0.020 |
Why?
| | Metabolic Networks and Pathways | 1 | 2008 | 180 | 0.020 |
Why?
| | Age Distribution | 1 | 2007 | 390 | 0.020 |
Why?
| | Iodide Peroxidase | 1 | 2005 | 28 | 0.010 |
Why?
| | Thyroglobulin | 1 | 2005 | 27 | 0.010 |
Why?
| | Rats | 2 | 2004 | 5639 | 0.010 |
Why?
| | Integrin alpha Chains | 1 | 2004 | 24 | 0.010 |
Why?
| | United States | 1 | 2002 | 14691 | 0.010 |
Why?
| | Family Health | 1 | 2005 | 196 | 0.010 |
Why?
| | Histocompatibility Testing | 1 | 2004 | 126 | 0.010 |
Why?
| | False Positive Reactions | 1 | 2004 | 115 | 0.010 |
Why?
| | B7-1 Antigen | 1 | 2004 | 58 | 0.010 |
Why?
| | Endocrine System | 1 | 2004 | 20 | 0.010 |
Why?
| | Single-Blind Method | 1 | 2004 | 282 | 0.010 |
Why?
| | Disease Models, Animal | 2 | 2004 | 4282 | 0.010 |
Why?
| | HLA Antigens | 1 | 2005 | 237 | 0.010 |
Why?
| | Cyclophosphamide | 1 | 2003 | 247 | 0.010 |
Why?
| | T-Box Domain Proteins | 1 | 2003 | 98 | 0.010 |
Why?
| | Species Specificity | 1 | 2004 | 586 | 0.010 |
Why?
| | Enkephalins | 1 | 2002 | 20 | 0.010 |
Why?
| | Delivery, Obstetric | 1 | 2004 | 145 | 0.010 |
Why?
| | Pyridinium Compounds | 1 | 2002 | 26 | 0.010 |
Why?
| | Reference Values | 1 | 2004 | 816 | 0.010 |
Why?
| | Mice, Inbred C57BL | 2 | 2004 | 5750 | 0.010 |
Why?
| | CD8 Antigens | 1 | 2002 | 75 | 0.010 |
Why?
| | HLA-A Antigens | 1 | 2002 | 55 | 0.010 |
Why?
| | Antigens, CD | 1 | 2004 | 521 | 0.010 |
Why?
| | Models, Immunological | 1 | 2002 | 100 | 0.010 |
Why?
| | Chronic Disease | 1 | 2008 | 1786 | 0.010 |
Why?
| | Antibodies | 1 | 2003 | 411 | 0.010 |
Why?
| | Gene Expression Profiling | 1 | 2008 | 1772 | 0.010 |
Why?
| | Glucagon | 1 | 2002 | 109 | 0.010 |
Why?
| | Major Histocompatibility Complex | 1 | 2002 | 227 | 0.010 |
Why?
| | Regression Analysis | 1 | 2004 | 1022 | 0.010 |
Why?
| | Cells, Cultured | 1 | 2008 | 4192 | 0.010 |
Why?
| | Survival Analysis | 1 | 2003 | 1321 | 0.010 |
Why?
| | Histocompatibility Antigens Class II | 1 | 2002 | 368 | 0.010 |
Why?
| | Amino Acid Sequence | 1 | 2004 | 2138 | 0.010 |
Why?
| | Genetic Predisposition to Disease | 1 | 2008 | 2412 | 0.010 |
Why?
| | Proteins | 1 | 2004 | 1009 | 0.010 |
Why?
| | Immunity, Innate | 1 | 2004 | 825 | 0.010 |
Why?
| | Immunohistochemistry | 1 | 2002 | 1733 | 0.010 |
Why?
| | Vaccination | 1 | 2003 | 1377 | 0.010 |
Why?
| | Pregnancy | 1 | 2004 | 6729 | 0.010 |
Why?
|
|
Yu's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|